ISIN | AT0000A1FNT0 |
---|---|
Valor Number | 28871817 |
Bloomberg Global ID | |
Fund Name | DSC Equity Fund – Healthcare A|A |
Fund Provider |
Dreyfus Söhne & Cie AG, Banquiers
Aeschenvorstadt 16 | Postfach 4051 Basel Schweiz Phone: +41 61 286 66 66 Web: https://www.dreyfusbank.ch |
Fund Provider | Dreyfus Söhne & Cie AG, Banquiers |
Representative in Switzerland |
Dreyfus Söhne & Cie AG, Banquiers Basel |
Distributor(s) |
Dreyfus Söhne & Cie AG, Banquiers Basel |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Distribution |
Home Country | Austria |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 242.06 CHF | 18.09.2024 |
---|---|---|
Previous Price * | 243.90 CHF | 17.09.2024 |
52 Week High * | 246.77 CHF | 03.09.2024 |
52 Week Low * | 200.58 CHF | 30.10.2023 |
NAV * | 242.06 CHF | 18.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 41,387,253 | |
Unit/Share Assets *** | 39,174,880 | |
Trading Information SIX |
YTD Performance | +15.34% |
29.12.2023 - 18.09.2024
29.12.2023 18.09.2024 |
---|---|---|
1 month | -0.89% |
19.08.2024 - 18.09.2024
19.08.2024 18.09.2024 |
3 months | +2.82% |
18.06.2024 - 18.09.2024
18.06.2024 18.09.2024 |
6 months | +3.76% |
18.03.2024 - 18.09.2024
18.03.2024 18.09.2024 |
1 year | +10.66% |
18.09.2023 - 18.09.2024
18.09.2023 18.09.2024 |
2 years | +9.29% |
19.09.2022 - 18.09.2024
19.09.2022 18.09.2024 |
3 years | -1.54% |
20.09.2021 - 18.09.2024
20.09.2021 18.09.2024 |
5 years | +21.79% |
18.09.2019 - 18.09.2024
18.09.2019 18.09.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 5.67% | |
---|---|---|
Johnson & Johnson | 5.62% | |
Novo Nordisk A/S Class B | 5.58% | |
UnitedHealth Group Inc | 5.43% | |
Merck & Co Inc | 4.29% | |
Regeneron Pharmaceuticals Inc | 4.09% | |
Abbott Laboratories | 3.56% | |
Amgen Inc | 3.41% | |
AbbVie Inc | 3.34% | |
iShares MSCI Wld Hlth Cr Sect ESGETF$Inc | 3.02% | |
Last data update | 31.07.2024 |
TER | 1.53% |
---|---|
TER date | 30.04.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.53% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |